Company: ELV
Filing Date: 2025-07-17
Form Type: 10-Q
Source: 0001156039-25-000114
Chunk: 77

Company: Elevance Health, Inc.
Filing Date: 2025-07-17
Form: 10-Q
Item: Item 8
Chunk 77
---
 INFORMATION

ITEM 1.    LEGAL PROCEEDINGS

For information regarding legal proceedings at June 30, 2025, see the “Litigation and Regulatory Proceedings” and “Other Contingencies” sections of Note 11, “Commitments and Contingencies” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, which information is incorporated herein by reference.

ITEM 1A.    RISK FACTORS

There have been no material changes to the risk factors disclosed in Part I, Item 1A of our 2024 Annual Report on Form 10-K.

-56-

ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities

The following table presents information related to our repurchases of common stock for the periods indicated:

PeriodTotal Numberof SharesPurchased1 AveragePrice Paidper ShareTotal Numberof SharesPurchasedas Partof PubliclyAnnouncedPrograms2ApproximateDollar Valueof Sharesthat May YetBe PurchasedUnder thePrograms(in millions, except share and per share data)    April 1, 2025 to April 30, 2025567,084 $427.05 565,952 $8,179 May 1, 2025 to May 31, 2025112,510 390.43 111,154 8,136 June 1, 2025 to June 30, 2025248,413 380.11 247,315 8,042 928,007 924,421 

1    Total number of shares purchased includes 3,586 shares delivered to or withheld by us in connection with employee payroll tax withholding upon the exercise or vesting of stock awards. Stock grants to employees and directors and stock issued for stock option plans and stock purchase plans in the consolidated changes in equity are shown net of these shares purchased.

2    Represents the number of shares repurchased through the common stock repurchase program authorized by our Board of Directors, which the Board of Directors evaluates periodically. During the three months ended June 30, 2025, we repurchased 924,421 shares at an aggregate cost of $379 under the program, including the cost of options to purchase shares. The Board of Directors has authorized our common stock repurchase program since